TipRanks on MSN
Structure Therapeutics stock (GPCR) spikes 102% as obesity trial beats Eli Lilly, Novo Nordisk
Biotech Structure Therapeutics’ (GPCR) shares rallied 102.49% on Monday after mid-stage data for its obesity pill topped ...
An AI-driven computational toolkit, Gcoupler, integrates ligand design, statistical modeling, and graph neural networks to predict endogenous metabolites that allosterically modulate the GPCR–Gα ...
Structure Therapeutics has a promising pipeline of product candidates, including GSBR-1290, a GLP-1R agonist for diabetes and obesity, and APJR and LPA1R agonists and antagonists for various ...
Zacks Investment Research on MSN
GPCR stock soars 102% on strong phase II obesity data for Aleniglipron
Shares of Structure Therapeutics GPCR skyrocketed 102.5% after the company reported positive top-line data from the ACCESS ...
Structure Therapeutics Inc. (NASDAQ:GPCR – Get Free Report) has been given an average rating of “Buy” by the eight research firms that are presently covering the firm, Marketbeat.com reports. Eight ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback